Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viketo
- Development stage
- Unknown
- Lead developer
- Neuraxpharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Viketo is a brand name suffix/prefix used by the pharmaceutical company Invent Farma and its subsidiary Laboratorios Lesvi for several generic drug products marketed in European countries, including Germany, Poland, Greece, and Romania. Notable medications under this brand include Olanzapin Viketo (olanzapine, an atypical antipsychotic), Quetiapin Viketo (quetiapine, another atypical antipsychotic), and Montelukast Viketo (montelukast, a leukotriene receptor antagonist used for asthma and allergic rhinitis). Because 'Viketo' does not refer to a single active pharmaceutical ingredient but rather a line of generic products, it is classified as a non-specific drug name.
- Brand names
- Montelukast ViketoOlanzapin ViketoOlanzapina ViketoQuetiapin ViketoQuetiapinum ViketoViketo
Beyond the preview
Go deeper on Viketo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viketo.